Poly-Ingredient Formulation Bresol(®) Ameliorates Experimental Chronic Obstructive Pulmonary Disease (COPD) in Rats.
Poly-Ingredient Formulation Bresol(®) Ameliorates Experimental Chronic Obstructive Pulmonary Disease (COPD) in Rats.
复制标题
DOI：
10.3797/scipharm.1212-06
复制
发表时间：
2013-07
影响因子：
2.5
通讯作者：
Patki PS
中科院分区：
文献类型：
--
作者：
Rafiq M;Viswanatha GL;Suryakanth DA;Azeemuddin M;Jagadeesh M;Dhanush K;Patki PS
在本研究中，在香烟烟雾（CS）诱导的大鼠COPD实验模型中评估了Bresol®（一种多草药制剂）的保护作用。每天暴露于CS 10分钟，持续7周，导致阳性未处理对照动物的支气管肺泡灌洗液（BALF）中TNF-α（p<0.01）和总蛋白（p<0.01）显著升高，表明肺中正在进行的炎症过程。此外，组织病理学结果证实了气管和肺中存在病理学损伤。用Bresol®（250和500 mg/kg，p.o.）通过将TNF-α和总蛋白水平维持在正常范围内，对CS诱导的肺异常显示出显著的剂量依赖性抗炎作用。此外，Bresol®处理的动物显示气管和肺的正常细胞结构。总之，Bresol®在大鼠中显示出针对CS诱导的肺和气管损伤的剂量依赖性保护，这进一步表明，Bresol®是有用的愈合剂，可以帮助减缓COPD的进展，并减少患者的恶化。
In the present study, the protective effect of Bresol® – a polyherbal formulation – was evaluated in an experimental model of cigarette smoke (CS)-induced COPD in rats. Ten minutes daily exposure to CS for 7 weeks caused significant elevation of TNF-α (p<0.01) and total protein (p<0.01) in the bronchoalveolar lavage fluid (BALF) of positive untreated control animals, indicating ongoing inflammatory process in the lungs. Further, histopathological findings have confirmed the presence of pathological lesions in the trachea and lungs. Five weeks of post-treatment with Bresol® (250 and 500 mg/kg, p.o.) showed significant and dose-dependent anti-inflammatory effects against CS-induced lung abnormalities by maintaining the TNF-α and total protein levels within the normal range. Additionally, Bresol®-treated animals showed normal cyto-architecture of the trachea and lungs. In conclusion, Bresol® showed dose-dependent protection against CS-induced lung and tracheal injury in rats, which further indicates, Bresol® is a useful healing agent, may help to decelerate the progression of COPD, and reduce the exacerbations in patients.